Recombinant monoclonal antibody to CD22. Clone RFB4-PE38 is a chimeric antibody that can be potentially used in the treatment of leukemia and lymphoma.
Figure 1 Cytotoxicity of RFB4(dsFv)PE38 for various cell lines after a 24-hour incubation.
Leucine incorporation is expressed as a percentage of cpm incorporated by control cells incubated without immunotoxin. (○), CA46; (▵), JD-38; (+), Raji; (▪), Namalwa; (•), Daudi; (▴), HUT102. Data are representative of at least three trials for each cell line.
Mansfield, E., Amlot, P., Pastan, I., & FitzGerald, D. J. (1997). Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood, The Journal of the American Society of Hematology, 90(5), 2020-2026.
Figure 2 The relative binding activity of RFB4(dsFv)PE38 compared with native antibody on CA46 cells.
Whole antibody and recombinant immunotoxin were used to compete for binding of trace amounts of 125I-labeled RFB4 IgG. Counts competed are expressed as a percentage of counts from cells that were incubated without any competitor. (□), RFB4 IgG; (▴), RFB4(dsFv)PE38.
Mansfield, E., Amlot, P., Pastan, I., & FitzGerald, D. J. (1997). Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood, The Journal of the American Society of Hematology, 90(5), 2020-2026.
Figure 3 Antitumor activity of RFB4(dsFv)PE38.
Athymic nude mice irradiated on day −3 were inoculated with 107 CA46 cells on day 0. Beginning on day 1, injections of 5, 2, or 1 μg RFB4(dsFv)PE38 or PBS/0.2% BSA were given every day for four doses. Tumor growth was monitored by measuring tumor volume and is expressed as the average tumor volume of each group. Control mice were killed before the end of the 21-day observation period because their tumor volumes would have exceeded humane limits. (□), 5 μg; (▴), 2 μg; (○), 1 μg; (▪), PBS/0.2% BSA diluent control. Data are from one of two experiments that gave similar results.
Mansfield, E., Amlot, P., Pastan, I., & FitzGerald, D. J. (1997). Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood, The Journal of the American Society of Hematology, 90(5), 2020-2026.
Figure 4 Activity of BL22 against CD22-expressing human ALL blasts.
CD22 was expressed by primary patient blasts. Anti-CD22 antibody binding capacity per cell quantified in 54 primary patient samples revealed an average CD22 density of 451 - 16,523 sites per cell (median, 4,062).
Wayne, A. S., Kreitman, R. J., Findley, H. W., Lew, G., Delbrook, C., Steinberg, S. M., ... & Pastan, I. (2010). Anti-CD22 immunotoxin RFB4 (dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clinical Cancer Research, 16(6), 1894-1903.
Figure 5 The impact of disease burden on BL22 pharmacokinetics.
Cycle 1 BL22 clearance correlated with the absolute peripheral blood blast count (Spearman correlation r = 0.73, 95% confidence interval, 0.45 - 0.88; p < 0.0001)
Wayne, A. S., Kreitman, R. J., Findley, H. W., Lew, G., Delbrook, C., Steinberg, S. M., ... & Pastan, I. (2010). Anti-CD22 immunotoxin RFB4 (dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clinical Cancer Research, 16(6), 1894-1903.
Figure 6 Hematologic improvement after BL22.
Bone marrow biopsies reveal decrease in blast infiltration and increase in normal hematopoietic precursors. TdT (terminal deoxynucleotidyl transferase) immunohistochemistry (blasts stain brown). (Subject #20)
Wayne, A. S., Kreitman, R. J., Findley, H. W., Lew, G., Delbrook, C., Steinberg, S. M., ... & Pastan, I. (2010). Anti-CD22 immunotoxin RFB4 (dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clinical Cancer Research, 16(6), 1894-1903.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1248z-F(E) | Recombinant Anti-Human CD22 Antibody Fab Fragment | IP, RIA, FuncS | Fab |
HPAB-0194-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0194-LSX-F(E)) | ELISA | Mouse Fab |
HPAB-0195-LSX-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0195-LSX-F(E)) | ELISA | Human Fab |
HPAB-0196-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0196-LSX-F(E)) | ELISA | Mouse Fab |
HPAB-0197-LSX-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0197-LSX-F(E)) | ELISA | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-183-F(E) | Anti-Human CD22 Recombinant Antibody (Moxetumomab Pasudotox) | FuncS, IF, Neut, ELISA, FC, IP, ICC | Fv - disulfide stabilized |
TAB-047-F(E) | Anti-Human CD22 Recombinant Antibody Fab Fragment(Bectumomab) | ELISA, FC, IP, FuncS, IF, Neut, WB | Fab' - G2a - kappa |
TAB-1714CL-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1714CL-F(E)) | ELISA, WB | Mouse Fab |
TAB-1723CL-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1723CL-F(E)) | Inhib | Mouse Fab |
TAB-1728CL-F(E) | Anti-Human CD22 Recombinant Antibody Fab Fragment (RFB4) | IF, FC |
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L048E | anti-CD22 immunotoxin RFB4 (scFv)-PE | Cytotoxicity assay, Functional assay | |
AGTO-L048D | anti-CD22 immunotoxin RFB4 (scFv)-DT | Cytotoxicity assay, Functional assay | |
AGTO-L048G | anti-CD22 immunotoxin RFB4 (scFv)-Gel | Cytotoxicity assay, Functional assay | |
AGTO-L048R | anti-CD22 immunotoxin RFB4 (scFv)-RTA | Cytotoxicity assay, Functional assay | |
AGTO-L048S | anti-CD22 immunotoxin RFB4 (scFv)-Sap | Cytotoxicity assay, Functional assay |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1715CL | Anti-Human CD22 Recombinant Antibody (12C5) | Cyt, FuncS | Fully human antibody |
TAB-0196CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (hLL2) | ELISA, In vivo | |
TAB-0197CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (hLL2-Cys) | ELISA, In vivo | |
TAB-1721CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (CD22.1) | ELISA, FC, FuncS | Human antibody |
TAB-1722CL-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (CD22.2) | ELISA, FC, FuncS | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1724CL | Human Anti-CD22 Recombinant Antibody (TAB-1724CL) | Inhib | Chimeric (mouse/human) IgG1, κ |
TAB-1724CL-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1724CL-S(P)) | Inhib | Mouse scFv |
TAB-001LC | Human Anti-CD22 Recombinant Antibody (TAB-001LC) | ELISA | Chimeric antibody (mouse/human) |
TAB-001LC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-001LC-S(P)) | ELISA | Mouse scFv |
TAB-001LC-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-001LC-F(E)) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1725CL-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1725CL-F(E)) | Block, Cyt, ELISA, FuncS | Humanized Fab |
TAB-1729CL-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1729CL-F(E)) | IF, FC | Humanized Fab |
TAB-002LC | Anti-Human CD22 Recombinant Antibody (VM1000) | FC, ELISA, SPR, FuncS | Humanized antibody |
TAB-002LC-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (VM1000) | ELISA, SPR | Humanized antibody |
TAB-002LC-F(E) | Anti-Human CD22 Recombinant Antibody Fab Fragment (VM1000) | ELISA, SPR | Humanized antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-001LC | Recombinant Anti-Human CD22 Antibody (Fab glycosylation) | ELISA, FC | Mouse antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-111LC | Recombinant Anti-Human CD22 Antibody (Fc glycosylation) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-315CQ | Rat Anti-CD22 Recombinant Antibody (clone 2D6) | Block | Rat IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0545 | Hi-Affi™ Rabbit Anti-CD22 Recombinant Antibody (clone DS545AB) | IP, WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0249-FY | Recombinant Human Anti-CD22 Antibody | F | Human IgG1 |
FN-070CQ | Mouse Anti-CD22 Recombinant Antibody (clone IS7) | FC | Mouse IgG1 |
FN-088CQ | Mouse Anti-CD22 Recombinant Antibody (clone Cy34.1) | Depletion, FC, IP | Mouse IgG1 |
HPAB-1899LY | Mouse Anti-CD22 Recombinant Antibody (HPAB-1899LY) | ELISA, Inhib | Mouse IgG |
HPAB-1900LY | Mouse Anti-CD22 Recombinant Antibody (HPAB-1900LY) | ELISA, Inhib | Mouse IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0249-FY-S(P) | Recombinant Human Anti-CD22 Antibody scFv Fragment | F | Human scFv |
HPAB-0034-YJ-S(P) | Mouse Anti-CD22 Recombinant Antibody (clone HB22-23); scFv Fragment | Block | Mouse scFv |
HPAB-0709-FY-F(E) | Mouse Anti-CD22 Recombinant Antibody (clone AB008); scFv Fragment | ELISA | Mouse scFv |
HPAB-0370-FY-S(P) | Human Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-0370-FY-S(P)) | ELISA | Humanized scFv |
HPAB-2052-FY-S(P) | Human Anti-CD22 Recombinant Antibody (clone B28); scFv Fragment | FC | Human scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-176 | Afuco™ Anti-CD22 ADCC Recombinant Antibody (Epratuzumab), ADCC Enhanced | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-198 | Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
There are currently no Customer reviews or questions for HPAB-0204-LSX. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.